Leading Clinical Investigators and Physicians to Address Key Issues for Clinical-Stage Biopharmaceuticals at Seventh Annual BIO Investor Forum

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today announced that 28 renowned clinicians and investigators will be featured in Therapeutic Workshops™ at the Seventh Annual BIO Investor Forum on October 29-31 at the Palace Hotel in San Francisco, Calif. A distinguished panel of industry leaders hand-selected these experts to discuss biotechnology pipeline innovation and the latest in clinical strategy.

“BIO is committed to providing high-quality and independent forums where clinicians and industry leaders can drive insightful discussion on innovative clinical-stage products pioneered by emerging biotech companies.”

The clinicians and investigators represent prestigious academic institutions and medical foundations. In addition, heads of clinical development from leading public and private biotechnology companies will participate on these panels.

“This is the first year in which the BIO Investor Forum, together with Gerson Lehrman Group, has made a robust investment in inviting clinical thought leaders knowledgeable about the biotech and pharmaceutical industries to speak directly to investors,” said Jim Greenwood, president and CEO of BIO. “BIO is committed to providing high-quality and independent forums where clinicians and industry leaders can drive insightful discussion on innovative clinical-stage products pioneered by emerging biotech companies.”

BIO Investor Forum’s Therapeutic Workshops are selected according to the breadth and innovation in the particular field, and whether the pipeline is mature enough to support clinical-stage development programs and anticipated near-term catalysts such as upcoming regulatory approvals, clinical data, FDA Advisory Committee meetings and/or prospective commercial partnerships.

BIO Investor Forum Therapeutic Workshops™

Hematology: Pre-ASH Primer: Hematology Heavy Hitters Discuss What’s on the Horizon

Thursday, October 30, 9:30am-10:45am

Reni Benjamin, PhD; Senior Biotechnology Analyst, Managing Director; Rodman & Renshaw, LLC
Alan Colowick, MD; Chief Executive Officer; Gloucester Pharmaceuticals
Arthur C. Louie, MD, FACP; Chief Medical Officer; Celator Pharmaceuticals
Mark L. Reisenauer; Senior Vice President and Chief Commercial Officer; Micromet, Inc.
Steven Coutre, MD; Associate Professor of Medicine, Stanford University School of Medicine; Director of the Outpatient Hematology Clinic, Stanford Hospital

Fibromyalgia: First Things First - New Approaches to Treating Fibromyalgia Are Coming into Focus but Where do Clinicians Start?

Thursday, October 30, 9:30am-10:45am

Corey Davis, PhD; Managing Director, Senior Specialty Pharmaceuticals Analyst; Natixis Bleichroeder
Lynne K. Matallana; President and Founder; National Fibromyalgia Association, Anaheim
Philip Mease, MD; Director of Seattle Rheumatology Associates; Director of the Swedish Hill Hospital Rheumatology Clinical Research Division; Clinical Professor, University of Washington, Seattle
Jon Russell, MD, PhD; Director of the University Clinical Research Center; Associate Professor of Medicine, University of Texas Health Science Center, San Antonio
Andrew Holman, MD; Associate Clinical Professor of Medicine, University of Washington, Seattle

Epilepsy: Targeting Seizures Disorders - A Pipeline at the Threshold of a Broader CNS Opportunity

Thursday, October 30, 9:30-10:45am

Samuel P. Wertheimer, PhD; Private Equity Partner; OrbiMed Advisors LLC
Elizabeth Garofalo, MD; Consultant Neurologist, Acting Medical Officer; Marinus Pharmaceuticals Inc.
Seth V. Hetherington, MD; Senior Vice President of Clinical and Regulatory Affairs; Icagen, Inc.
Roger Porter, MD; Adjunct Professor of Pharmacology, Uniformed Services University of the Health Sciences, Philadelphia
David Treiman, MD; Newsome Chair in Epileptology; Director of the Epilepsy Center; Vice-chair of Neurology at the Barrow Neurological Institute in Phoenix; Professor of Neuroscience and Bioengineering at Arizona State University, Tempe

Congestive Heart Failure: New Therapeutics to Improve CHF Outcomes

Thursday, October 30, 9:30-10:45am

Michael G. King, Jr; Managing Director and Director of Research; Rodman & Renshaw, LLC
Detlef Albrecht, MD; Chief Medical Officer and Senior Vice President of Drug Development; Relypsa, Inc.
Michael R. Bristow, MD, PhD, FACC; Professor of Medicine in Cardiology; University of Colorado Denver School of Medicine; Co-Director of the University of Colorado Cardiovascular Institute; Chief Science and Medical Officer, ARCA biopharma
Andrew A. Wolff, MD; Chief Medical Officer and Senior Vice President of Clinical Research and Development; Cytokinetics, Inc.
John Teerlink, MD; Associate Professor of Medicine, University of California, San Francisco; Director of the Heart Failure Clinic, Director of Clinical Echocardiography at the San Francisco Veterans Affairs Medical Center
Barry Massie, MD; Professor of Medicine at the University of California at San Francisco; Chief Cardiology Division at San Francisco Veterans Affairs Medical Center

Osteoporosis: Opportunity in Osteoporosis and Bone Metabolism Disorders is Spurring Pipeline Growth

Thursday, October 30, 5:00-6:15pm

Liana Moussatos, PhD; Senior Biotechnology/Biopharmaceutical Analyst; Pacific Growth Equities LLC
Brian MacDonald, MD, ChB, PhD; Chief Executive Officer; Zelos Therapeutics
Michael McClung, MD; Founding Director, Oregon Osteoporosis Center, Portland
John Bilezikian, MD; Chief of Metabolic Disease Unit, Chief of the Division of Endocrinology and Professor at the College of Physicians and Surgeons, Columbia University, New York

Cancer: Bullseye: Novel Targets in Oncology

Thursday, October 30, 5:00-6:15pm

Jason Kantor, PhD; Managing Director; RBC Capital Markets
Lori Kunkel, MD; Chief Medical Officer; Proteolix, Inc.
Daniel R. Passeri; President and Chief Executive Officer; Curis, Inc.
Pamela Munster, MD; Associate Professor of Dept of Medicine (Hematology/Oncology); Director of Early Phase Clinical Trials Program; Associate Director of Investigational Therapeutics, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
Sunil Sharma, MD; Chief of the Section of GI Oncology and Clinical Phase 1 Unit at Nevada Cancer Institute, Las Vegas

Lung Cancer: Changing Paradigms in Lung Cancer Care and Advances in the Pipeline

Friday, October 31, 9:45-11:00am

Gregory K. Frykman, MD; Senior Vice President, Pharmaceutical and Biotechnology Analyst; Stanford Group Company
David Apelian, MD, PhD, MBA; Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer; GlobeImmune
Philippe Bishop, MD; Vice President, Clinical Development, Avastin; Genentech
Thomas J. Lynch, MD; Chief of Hematology and Oncology, Director of the Center for Thoracic Cancers at Massachusetts General Hospital; Professor of Medicine at Harvard Medical School
Renato G. Martins, MD, MPH; Medical Director of Thoracic Oncology; Seattle Cancer Care Alliance

A Focus on Neurodegeneration - Huntington’s and Parkinson’s Diseases

Friday, October 31, 9:45-11:00am

William Ho; Vice President and Senior Research Analyst; Bank of America Securities LLC
David T. Hung, MD; President, Chief Executive Officer and Director; Medivation, Inc.
Jeffrey M. Ostrove, PhD; President and Chief Executive Officer; Ceregene, Inc.
Michael Geschwind, MD, PhD; Assistant Professor of Neurology, University of California, San Francisco
J. William Langston MD; Scientific Director and Chief Executive Officer; The Parkinson's Institute

Cystic Fibrosis: Come up for Air! What’s in the Pipeline for Cystic Fibrosis?

Friday, October 31, 9:45-11:00am

Liana Moussatos, PhD; Senior Biotechnology/Biopharmaceutical Analyst, Pacific Growth Equities LLC
Temitayo Ajayi, MD; Director of Clinical Development; PTC Therapeutics
Amy E. Schaberg, RN, BSN; Vice President, Clinical Research; Inspire Pharmaceuticals
Richard Moss, MD; Professor of Pediatrics, Director of Cystic Fibrosis Center, Chief of the Division of Allergy- Immunology, Stanford University
L. Terry Spencer, MD; Director of Cystic Fibrosis Center, Director of Clinical Research, Division of Respiratory Diseases, Children’s Hospital Boston

To register for the BIO Investor Forum, please visit http://investorforum.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.

Private and public biopharmaceutical companies interested in speaking at the conference are encouraged to apply by contacting BIO Customer Service at biopartnering@bio.org or 866.356.5155 (US), 1.202.962.6666 (International).

The BIO Investor Forum is a national investor conference featuring leading private and emerging public companies. The meeting attracts sophisticated healthcare venture and private equity investors, buy-side investors and research analysts. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and mature biotechnology companies.

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Upcoming BIO Events

Intellectual Property Council Committee Fall Conference and Meeting

October 20-22, 2008

Orlando, Fla.

BIO HR Conference 2008

October 26-28, 2008

San Diego, Calif.

BIO-LES Advanced Business Development Course

October 27-29, 2008

San Francisco, Calif.

Seventh Annual BIO Investor Forum

October 29-31, 2008